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Abstract
Background: The initial treatm ent o f acute necrotizing pancreatitis is conservative. Intervention 
is indicated in patients w ith (suspected) infected necrotizing pancreatitis. In the Netherlands, the 
standard intervention is necrosectomy by laparotomy followed by continuous postoperative lavage 
(CPL). In recent years several minimally invasive strategies have been introduced. So far, these 
strategies have never been compared in a randomised controlled trial. The PANTER study 
(PAncreatitis, Necrosectomy versus sTEp up appRoach) was conceived to  yield the evidence 
needed fo r a considered policy decision.
Methods/design: 88 patients w ith (suspected) infected necrotizing pancreatitis w ill be randomly 
allocated to  either group A) minimally invasive 'step-up approach' starting w ith drainage followed, 
if necessary, by videoscopic assisted retroperitoneal debridement (VARD) o r  group B) maximal 
necrosectomy by laparotomy. Both procedures are followed by CPL. Patients w ill be recruited 
from  20 hospitals, including all Dutch university medical centres, over a 3-year period. The primary 
endpoint is the proportion o f patients suffering from  postoperative major m orbidity and mortality. 
Secondary endpoints are complications, new onset sepsis, length o f hospital and intensive care stay, 
quality o f life and tota l (direct and indirect) costs. To demonstrate that the 'step-up approach' can 
reduce the major m orbidity and m ortality rate from  45 to  16%, w ith 80% power at 5% alpha, a total 
sample size o f 88 patients was calculated.
Discussion: The PANTER-study is a randomised controlled tria l that w ill provide evidence on the 
merits o f a minimally invasive 'step-up approach' in patients w ith (suspected) infected necrotizing 
pancreatitis.
Background
The initial treatment of acute necrotizing pancreatitis is 
conservative [1-4]. Once (peri-)pancreatic necrosis 
becomes infected mortality increases steeply [3,4]. Inter­
vention is indicated when infection of (peri-)pancreatic 
necrosis is proven by fine needle aspiration (FNA), when 
(peri-)pancreatic air collections in the necrotic cavity are 
depicted on computer tomography (CT) scan or when 
sepsis persists despite maximal support on the intensive 
care unit. Surgical intervention within the first 14 days 
after the onset of symptoms should be averted because of 
notoriously poor outcome in this phase of disease [4,5]. 
Organ failure needing intensive care treatment during the 
first two weeks should be interpreted as a complication of 
a systemic inflammatory response syndrome (SIRS).
There is no consensus in the literature on the optimal sur­
gical strategy in infected necrotizing pancreatitis. In a 
recent systematic review we demonstrated that necrosec- 
tomy by laparotomy was accompanied by high mortality 
rates (15-27% ) and considerable morbidity [6].
In recent years radiologists, gastrointestinal surgeons and 
gastroenterologists have adopted minimally invasive
strategies in infected necrotizing pancreatitis [7]. Initially 
only practiced in patients unfit for laparotomy, but in 
recent years indications seem to have expanded [8-11]. 
Percutaneous catheter drainage (PCD) [12-14]. endo­
scopic transgastric procedures [15,16]. and minimally 
invasive necrosectomy [9-11]. have been proposed as 
alternatives for necrosectomy by laparotomy. Although 
preliminary results are promising, current series are small, 
poorly comparable and a selection bias may have influ­
enced the results [7].
It has been reported that PCD obviates the need for surgi­
cal intervention in infected necrotizing pancreatitis in 30 
to 100 per cent of cases [12-14]. In these series committed 
radiologists repeatedly performed repeated drainage pro­
cedures using large bore catheters. It has been argued that 
because of the need for repeated procedures PCD can not 
easily be implemented in clinical practice [17]. However, 
we hypothesize that 'simple' drainage with regular bore 
(12-14 French) percutaneous catheters can also be bene­
ficial to the patient. Drainage of 'infected fluid under pres­
sure' may help the patient in dealing with the (peri­
) pancreatic necrosis and delay or even obviate surgical 
intervention in a relevant proportion of patients.
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Tab le  1: P rim ary  ou tco m e o f th e  P A N T E R  tria l; com plications  
a fte r firs t in tervention
Mortality
New-onset multi organ failure o r systemic complications #
Enteric fistula (either small o r large bowel)
Perforation of a visceral organ requiring intervention 
Bleeding requiring intervention*
# New onset failure of 2 o r more organ systems or systemic 
complications as listed in Table 2, occurring at the same moment in 
time.
*Surgical, endoscopic o r radiological
As a prelude to the present study a retrospective m ulti­
center study was performed in 11 hospitals in the Nether­
lands [8]. The outcome of the different interventional 
strategies in (infected) necrotizing pancreatitis was 
assessed. The strategy most often used was laparotomy 
with continuous postoperative lavage (CPL) (53/106 
patients) [8]. O f the patients treated with minimally inva­
sive surgery (n = 18), two-thirds had PCD prior to surgical 
intervention. During surgery the percutaneous drain was 
used as a 'guide wire' to facilitate retroperitoneal access to 
the infected collections. The results of minimally invasive 
surgery were favourable: 11% mortality as compared to 
25% after laparotomy and CPL. However, since selection 
bias may have played a role in the favourable results a ran­
domised controlled trial is warranted in order to define 
evidence-based surgery in infected necrotizing pancreati­
tis.
We anticipate that a minimally invasive 'step-up 
approach' results in a reduction in postoperative major 
morbidity and mortality. The PANTER trial is designed to 
compare a minimally invasive 'step-up approach'with a 
primary maximal necrosectomyby laparotomy. The 'step- 
up approach' consists of percutaneous or transgastric 
drainage when necessary followed by minimally invasive 
necrosectomy.
Methods/design 
Study objectives
To test the hypothesis that a minimally invasive 'step-up 
approach' will lead to a reduction of postoperative major
Tab le  2: Definitions o f organ fa ilure and systemic com plications
morbidity and mortality in patients with infected (peri- 
)pancreatic necrosis.
Primary endpoint
The primary endpoint is the proportion of patients with 
major morbidity or mortality, see Tables 1 and 2. Compli­
cations occurring subsequent to the first intervention after 
randomisation until three m onths after discharge from 
the hospital are compared.
Secondary endpoints
Secondary endpoints are 'minor' complications (such as 
pancreatic fistula, pancreatic pseudocyst requiring inter­
vention, pancreatic abscess, biliary strictures, incisional 
hernia requiring re-intervention and pancreatic insuffi­
ciency), new onset sepsis, new onset SIRS, total num ber of 
interventions, hospital and intensive care stay, quality of 
life and total (direct and indirect) costs.
Definitions
The definitions of the Atlanta classification are used. Pan­
creatic necrosis: focal area's of non-enhancing pancreatic 
parenchyma on contrast-enhanced computer tomography 
(CECT). Infected necrotizing pancreatitis: a positive culture 
of pancreatic or peripancreatic necrosis obtained by FNA 
or the presence of air in the collections on CECT. Suspected 
infected necrotizing pancreatitis: persisting sepsis or progres­
sive clinical deterioration despite maximal support on the 
intensive care unit in case of pancreatic and/or peripancre- 
atic necrosis.
Design of study
PANTER is a randomised controlled parallel group superi­
ority multicenter trial.
Participating centres
Twenty hospitals of the Dutch Acute Pancreatitis Study 
Group, including all Dutch university medical centres, 
will enrol patients (see Appendix).
Pre-randomisation treatment protocol
All patients with acute pancreatitis will be treated by a pre­
established treatment protocol consisting of enteral nutri­
tion via a nasojejunal tube and an early endoscopic retro-
Organ Failure Circulatory Systolic blood pressure less than 90 mm hg o r need for catecholamine support
Pulmonary
Renal
PaO2 60 mm Hg or less o r need for mechanical ventilation
creatinine level greater than 177 umol/L after rehydration o r o r need for
hemofiltration o r hemodialysis
Systemic complications Gastrointestinal bleeding more than 500 ml/24 hours
Disseminated intravascular coagulation platelets <100 x I09/L
Severe metabolic disturbance calcium level <1.87 mmol/L
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grade cholangiopancreatography (ERCP) with 
sphincterotomy in case of predicted severe biliary pancre­
atitis with or without obstructive cholangitis. No antibi­
otic prophylaxis will be administered. CECT will be 
performed in patients who fail to show clinical improve­
m ent after the first 7 days of hospital admission. Since 
many patients are referred from other centres, violation of 
the pre-randomisation treatment protocol is not an exclu­
sion criteria.
Registration
From all patients with (peri-)pancreatic necrosis, includ­
ing those who are not randomised and treated conserva­
tively, written informed consent will be obtained for 
prospective registration of age, gender, onset of symp­
toms, interventional procedures, hospital stay, intensive 
care stay and mortality (alternatively consent by proxy 
will be obtained for patients who are unable to give con­
sent eg. intubated patients).
Tim ing o f  in te rvention
Whenever possible it is attempted to delay surgical inter­
vention. Ideally, the first intervention would be per­
formed at least 30 days after onset of symptoms. Earlier 
intervention may be warranted in case of a rapidly deteri­
orating clinical condition. When infection is proven 
within the first 14 days, intervention may be postponed. 
Intervention within 14 days is only indicated in emergen­
cies such as bowel perforation, abdominal compartment 
syndrome or acute bleeding. Patients with these complica­
tions are not eligible for randomisation.
Eligibility criteria 
Inclusion crite ria
■ age equal to or above 18 years
■ pancreatic necrosis or peripancreatic necrosis detected 
on CECT.
■ patients in whom a decision for surgical intervention has 
been made because of (suspected) infected (peri-)pancre- 
atic necrosis
■ possibility of placing a drain (either percutaneous or 
endoscopic) in the collection(s)
■ written informed consent 
Exclusion c rite ria
■ previous drainage or surgical necrosectomy for (sus­
pected) infected pancreatic necrosis, including procedures 
performed in referring hospitals. ERCP with or without 
papillotomy is allowed.
■ previous exploratory laparotomy for acute abdomen and 
diagnosis of pancreatitis during laparotomy
■ acute flare-up of chronic pancreatitis
■ bleeding, abdominal compartment syndrome or perfo­
ration of a visceral organ as indication for intervention
■ post-abdominal surgery necrotizing pancreatitis
Rationale: previous drainage procedures or laparotomy 
make it impossible to study the isolated effect of drainage 
of 'infected fluid under pressure'. There is essentially no 
indication for necrosectomy in acute fluid collections, 
pancreatic abscesses or pseudocysts as these collections do 
not contain pancreatic necrosis or necrotic debris accord­
ing to the Atlanta Classification. When intervention is 
indicated in these types of collections this is performed by 
drainage procedures, although some pseudocysts may 
require surgical intervention [4]. Patients with chronic 
pancreatitis have an underlying disease with a course very 
different from acute pancreatitis. Patients with a second, 
third or fourth attack of acute pancreatitis are eligible for 
randomisation as long as there are no signs of chronic 
pancreatitis (calcification and/or pancreatic duct abnor­
malities).
Randomisation
Patients will be randomly assigned to group A ('step-up 
approach') or group B (laparotomy) as shown in the flow­
chart (see figure 1). Randomisation is performed by an 
Internet randomisation module (Julius Center for pri­
mary care and health sciences, UMC Utrecht, the Nether­
lands). Block-randomisation is used and the 
randomisation is stratified according to the ( im p o ss ib il­
ity of placing a percutaneous drain through the (prefera­
bly left) retroperitoneum, since this step is essential to 
perform minimally invasive necrosectomy.
Ethics
This study is conducted in accordance with the principles 
of the Declaration of Helsinki and 'good clinical practice' 
guidelines. The independent medical ethics committees 
of all 20 participating hospitals have approved the study 
protocol. Prior to randomisation, written informed con­
sent will be obtained from all patients (alternatively con­
sent by proxy will be obtained for patients who are unable 
to give consent, e.g., intubated patients).
Safety and quality control
The indication and timing of intervention in  necrotizing 
pancreatitis can be difficult. Therefore, prior to random i­
sation using CECT images and a 'summarized case report' 
an expert panel consisting of three surgeons (MAB, HSH, 
HGG), a gastroenterologist (RT) and three radiologists
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To be assessed for 
eligibility (n=151)
1
To be randomised 
(n=90)*
Not meeting randomisation 
criteria (n=38)
Refusal to participate (n=15) 
Other reasons (n=8)
Allocated to a ‘step-up approach’ (n=45)
I
Lost to follow up (n=1)
I
Complete data (n=44)
Allocated to laparotomy (n=45)
I
Lost to follow up (n=1)
I
Complete data (n=44)
Figure 1
PANTER according to  CONSORT.
(TLB, MSVL, JSL) will assess the indication and feasibility 
of surgical, gastroenterological or radiological interven­
tion. All procedures will be performed by experienced 
radiologists, gastroenterologists or gastrointestinal sur­
geons. All endo-/videoscopic procedures will be video­
taped. In case of a planned intervention, surgeons or 
radiologists from (neighbouring) participating hospitals 
and the trial coordinator will join the procedure in order 
to increase experience and enhance protocol-compliance. 
Every four m onths a study group meeting will be organ­
ised in which the CECT images and the 'summarized case 
report' of all newly randomised patients will be discussed. 
An independent monitoring-committee, consisting of two 
surgeons, a gastroenterologist, an epidemiologist and a 
radiologist, will discuss (serious) adverse events and give 
advice to the trial steering committee.
Statistical analysis
In ten tion -to -trea t
The analysis will be performed in accordance with inten- 
tion-to-treat (ITT) principle
Sam ple size and sequentia l in terim -analysis  
Sequential analysis is used to determine the difference in 
treatment effect on the primary endpoint (see Methods/ 
design section), therefore no fixed sample size estimate 
can be given [18]. Based on the results of the Dutch retro­
spective multicentre audit (mortality 25% versus 11%) 
and PCD results from the literature is anticipated that the
minimally invasive 'step-up approach' will reduce the 
occurrence of the primary endpoint from 45% to 16%. 
The expected reduction of mortality and morbidity are 
10% and 19% respectively. With 80% power at 5% alpha 
(two-sided) complete data from about 52-77 patients will 
be necessary to demonstrate this effect, if it truly exists. If 
no such effect appears, the trial will continue until 88 
patients are randomised and available for analysis as 'con­
ventional' sample size calculation with 80% power at 5% 
alpha (two-sided) would require 88 patients.
Descriptive methods will be used to assess the quality of 
the data, comparability of treatment groups and end­
points. Continuous sequential analysis will be performed 
with PEST (PEST 4: user manual. MPS Research Unit 
(2000), the University of Reading) according to the 
restricted procedure as described by Whitehead [18]. 
Every time an endpoint occurs, data management will 
send a blinded, updated dataset of all included patients to 
the biostatistician. If one of the boundaries of the sequen­
tial analysis plot is crossed during the analysis of the 
cumulative data, i.e. the difference in treatment is of at 
least the expected magnitude, the trial steering committee 
will be informed and will be advised to stop randomising 
new patients for the trial. The trial steering committee will 
not be advised to stop early when no relevant differences 
between the treatments are observed. Next to the primary 
analysis, the outcome of both groups will also be adjusted 
forimbalance in presence of preoperative (multi-) organ
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failure and timing of intervention (after 28 days). These 
factors, including possibility of performing VARD and the 
individual components of the primary endpoint will also 
be included in a multivariate and subgroupanalysis.
Feasibility
The recent retrospective survey showed that in a 3-year 
period 106 patients had undergone surgery for necrotiz­
ing pancreatitis in 11 of the 20 participating Dutch hospi­
tals [8]. It is expected that up to 25% of eligible patients 
will be excluded mainly because of interventions (percu­
taneous drainage or surgery) being performed prior to 
randomisation in referring centres. Taking further into 
account refusal of informed consent (10%), other reasons 
for drop-out (5%) and loss-to-follow-up (2.5%) it is con­
sidered possible to randomise and collect data on 88 
patients in 3 years time. After one year, the inclusion rate 
will be assessed. If accrual is too slow, additional centres 
will be invited to participate.
Post-randomisation treatment protocol
All patients receive oral nutrition. If this is no t tolerated, a 
nasojejunal feeding tube is introduced and enteral feeding 
is started [19]. If gastrointestinal feeding is contra-indi­
cated, the patient will receive parenteral nutrition. Antibi­
otic treatment, Imipenem-cilastatin therapy 500 mg 3 
times daily, is started in all patients with a maximum 
duration of fourteen days. Antibiotic treatment is 
switched based on blood cultures and culture from mate­
rial collected during drainage and/or surgical procedures. 
If cultures remain negative antibiotic treatment is 
stopped. Selective decontamination of the digestive tract 
is allowed.
Group A: minimally invasive 'step-up approach'
Step 1: D ra inage
A percutaneous drain (at least 12 French) is placed in the 
(peri-)pancreatic collection. Multiple drains may be indi­
cated in case of large or multiple collections. The preferred 
route is through the left retroperitoneum. If this is not 
possible a transperitoneal route is chosen. A right retro­
peritoneal route is allowed when it can be safely applied. 
If this is also not possible, an endoscopic transgastric 
drainage is performed with two 10 French drains (10 
French being the current maximal drain size for endo­
scopic procedures) including a nasocystic drain for flush­
ing. No continuous lavage system is installed. Drains are 
kept open by flushing with 50 ml saline once every 8-hrs 
shift by nursing staff. Extra saline may be used depending 
on the aspect of the return-fluid, the size of the collections 
on CECT, communication between drains and connec­
tions between collections. If more than 200 ml saline is 
used daily a drain fluid-balance chart is kept.
If there is no clinical improvement 72 hours after drain 
placement, this is considered a failure and a CECT is made 
to check the position of the drain. "Clinical improve­
ment" is defined as: improved function of at least two 
organ systems (circulatory, pulmonary, renal) within 72 
hours, or at least 10% improvement of two out of three 
parameters: leucocytes/temperature/CRP. If during the 
repeat CECT the position of the drain is adequate and no 
additional drainable collections are seen, the patient is 
taken to the operating room (step two). If the position of 
the drain is ¡«adequate a second drain is placed in the col­
lection.
Seventy-two hours after a second drainage-procedure the 
patient is again evaluated. In case of improvement, treat­
m ent is conservative; otherwise the patient will be taken 
to the operating room (step two). If after drainage, at any 
m om ent in time, a deterioration of at least two organ sys­
tems (circulatory, pulmonary, renal), or at least 10% dete­
rioration of two out of three parameters: leucocytes/ 
temperature/CRP occurs, step two is taken. Deterioration 
(of these parameters) by other infectious causes (e.g. an 
urinary tract infection) should be excluded.
Step tw o: videoscopic assisted re trop e riton ea l debridem en t 
The percutaneous retroperitoneal drain is used for video- 
scopic assisted retroperitoneal debridement (VARD). 
VARD has been used in several of the participating centres 
since 2000. The technique was recently described by Hor­
vath et fll[11]. See figure 2.
1. The patient is placed in a supine position with the left 
side elevated.
2. The left flank and the entire abdomen are prepared and 
draped.
3. Based on the position of the drain a 5 cm sub- or inter­
costal incision is made in the left flank.
4. With digital exploration the retroperitoneal drain is fol­
lowed into the collection.
5. The collection is opened and necrosectomy performed 
with ring forceps and suction device.
6. A long 10 mm trocar and a 10 mm long zero degree vid­
eoscope (laparoscope) are inserted through the incision 
in the retroperitoneum.
7. With the videoscope the cavity is inspected and remain­
ing, loosely adherent, necrosis is removed with a laparo­
scopic grasper or ring forceps. Note: it is no t considered 
mandatory to remove all necrotic material.
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Group A
Minimally invasive ‘step up approach’
Drain placement
1. Percutaneous through left retroperitoneum (preferred strategy)
2. Percutaneous transabdominal
3. Endoscopic transgastric
In case of clinical improvement# wait and see 
If no clinical improvement or deterioration, repeat CT-scan once§
t
Videoscopic Assisted Retroperiteoneal Debridement (VARD) 
If VARD is not possible, laparotomy similar to group B is performed. 
In both cases CPL >4L/24 hrs is installed
Group B 
Maximal necrosectomy
Laparotomy, maximal 
necrosectomy 
and continuous 
postoperative lavage 
(CPL) >4L/24hrs
Figure 2
PANTER flowchart. ® = randomisation. #In the intensive care: w ithin 72 hours, improved function o f at least tw o  organ systems 
(renal/respiratory/cardiovascular) o r in the ward: w ithin 72 hours, improvement o f tw o  o f these three parameters: leucocytes/ 
temperature/CRP. The w orst parameter is used. §No clinical improvement w ithin 72 hours after drainage is considered failure: 
repeat the CT-scan once to  check position o f the drains. If the position is adequate, and no additional drainable collections are 
seen, proceed to  surgery, if drain position is inadequate: repeat CT-guided percutaneous drainage (o r endoscopic transgastric 
drainage). If after the second drainage there is no clinical improvement w ithin 72 hours, proceed to  surgery. If repeat-drainage 
is not possible, patients proceed to  surgery.
8. Two large bore surgical drains are placed in the collec­
tion via the incision and the skin is closed between the 
drains.
If VARD is technically not feasible, laparotomy by bilat­
eral subcostal incisions is performed as in Group B. Out­
come of these patients will be analysed in group A 
according to the intention-to-treat principles.
Group B: maximal necrosectomy by laparotomy
Laparotomy is performed with a bilateral subcostal inci­
sion. The lesser sac is entered through the omentum and 
carefully inspected. Blunt debridement of all necrotic tis­
sue is performed. Two large bore drainage tubes are 
inserted through separate incisions with their tips in the 
lesser sac and necrotic cavities, the entrance to the lesser
sac is carefully closed to create a contained space for CPL 
[20]. In case of diffuse bleeding, it is advisable to perform 
packing with gauzes that are to be removed the next day. 
Consequently, the lavage system is then installed on the 
first postoperative day.
Both in group A and in group B, necrotic material is col­
lected during necrosectomy for culture and the total 
am ount of necrotic tissue collected is weighed and photo­
graphed.
Postoperative management
The postoperative management is similar in both groups. 
Continuous postoperative lavage with normal saline or 
peritoneal dialysis (CAPD) fluid is started. On the third 
postoperative day, the lavage should am ount to at least 10
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litres per 24 hours. CECT is performed one week after 
every drain placement and surgical intervention. Cathe­
ters are removed if collapse of the cavity is shown on 
CECT with contrast through the drainage system (or: on a 
sinogram of the cavity), and daily production of clear flu­
ids has decreased below 50 ml/24 hours. Patients can be 
discharged with catheters in place and continue irrigation 
at home. Time to final removal of the drains will be 
recorded.
Ind ication fo r re -in tervention
Re-intervention is performed 'on-demand'. Planned re­
intervention is only performed in case 'packing materials' 
have been left in-situ during the first procedure. A re-inter­
vention for removal of necrotic remnants is, whenever 
technically feasible, performed in accordance with the 
strategy the patient was initially assigned to. However, a 
pancreatic abscess (a collection consisting only of pus 
without necrosis) is treated by percutaneous drainage 
only.
D a ta  collection
Data are collected via a secured Internet module which 
was specifically designed for the PANTER trial (Julius 
Center for primary care and health sciences, UMC Utrecht, 
the Netherlands). Data are entered online bu t are not 
stored on the Internet. Sequential Organ Dysfunction 
Scores (SOFA) are noted at randomisation [21,22]. The 
SOFA score, major morbidity (Table 1) and other compli­
cations are registered every second day for the first m onth 
and twice weekly thereafter until discharge. Furthermore 
at any (re-)intervention the SOFA score, procedure-related 
data (length of procedure, blood-loss) and procedure- 
related complications are scored.
Data monitoring
There will be regular contact (by telephone, e-mail and 
site-visits) between the study coordinators and participat­
ing centres. Two study nurses will m onitor the entered 
data. Twice a year a m inimum of 10% of the data, includ­
ing all end points, will be verified (double-checked) with 
source data at the study site by an independent monitor.
Follow-up
Patients are observed during their hospital stay. Follow-up 
visits are planned after 3 and 6 months. For the primary 
endpoint, follow-up is completed at 3 m onths and for the 
secondary endpoints at 6 m onths after discharge, with a 
physical examination to exclude incisional hernia and 
ultrasonography to exclude a pancreatic pseudocyst.
Discussion
A recent Dutch retrospective multicenter study showed 
that laparotomy with CPL is the current standard for treat­
m ent of infected necrotizing pancreatitis as it is the tech­
nique most frequently used in the Netherlands with 
consistently and relatively good results [8]. In this series, 
mortality for the 'open-abdomen-strategy' was 70% 
(intention-to-treat analysis) which is unacceptably high. 
The 'experimental arm' in PANTER is a minimally invasive 
'step-up approach'. Notably, in necrotizing pancreatitis a 
minimally invasive approach does not only aim at m ini­
mising surgical stress, it is also part of a different treatment 
concept. We hypothesize that it is not necessary to remove 
all necrotic tissue in order to successfully treat patients 
with infected necrotizing pancreatitis. By performing 
drainage of 'infected fluid under pressure' the clinical con­
dition may improve and the necrotic tissue may success­
fully be dealt with by the patient's immune system. It is 
therefore not the goal of drainage to remove (peri-)pan- 
creatic necrosis but merely the infected fluid.
The second step of the minimally invasive 'step-up 
approach', 'VARD', is only performed if the first step fails. 
VARD combines endoscopic 'drain-tract' necrosectomy as 
first described by Carter et al[9]. and an open retroperito­
neal approach. In our opinion VARD has the advantage of 
endoscopic necrosectomy as it is minimally invasive. 
However, VARD lacks the disadvantages of being techni­
cally demanding and time consuming. In VARD the rela­
tively small 5 cm incision greatly facilitates the 'debulking' 
part. This will no t only reduce the operating time but also 
potentially reduce the num ber of procedures needed to 
remove the necrotic tissue.
It has been argued that minimally invasive procedures are 
only feasible in a small subgroup of necrotizing pancrea­
titis patients. Our group recently performed a feasibility 
study re-evaluating CT scans of 80 patients operated upon 
for (suspected) infected necrotizing pancreatitis and 
found that in the vast majority of patients PCD is techni­
cally feasible and that in  the majority of patients VARD is 
possible [23].
Currently, there are no randomised controlled trials com­
paring surgical techniques in necrotizing pancreatitis 
most likely due to low patient volumes, the heterogeneity 
of the disease and the highly individualized approach. 
The Dutch Acute Pancreatitis Study Group was founded to 
resolve several of these problems [24]. Since 2004, 15 of 
the 20 centres participating in PANTER are also participat­
ing in PROPATRIA, a placebo-controlled trial of probiotic 
prophylaxis in predicted severe acute pancreatitis [25]. 
Patients who initially are included in PROPATRIA are 
screened for eligibility in PANTER. Once a patient devel­
ops infected necrotizing pancreatitis the outcome for 
PROPATRIA is reached and he/she can be randomised for 
PANTER. With this already ongoing multicenter coopera­
tion the logistical and organisational problems are 
expected to be kept at a minimum.
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The sequential analysis of the primary outcome enables us 
to stop the trial as soon as sufficient evidence has accumu­
lated regarding both clinically relevant and statistically 
significant treatment difference. Compared to a conven­
tional fixed sample size sequential analysis on average 
requires less patients to show an expected effect if it truly 
exists [18]. This can be advantageous when the disorder is 
as rare as infected necrotizing pancreatitis. Moreover, as 
soon as the predefined threshold is passed randomisation 
may seize, thus preventing further patients to be subjected 
to an inferior treatment. If the presumed effect does not 
exist, based on conventional sample size calculations, 88 
patients will be randomised.
A possible disadvantage of the present study concept is the 
large num ber of centres participating. In the Netherlands 
centralisation has not reached a level that all patients are 
referred to tertiary centres [8,26]. However, the 20 hospi­
tals participating are amongst the largest of the 101 Dutch 
hospitals and all have experienced gastrointestinal sur­
geons, gastroenterologists and radiologists, including for 
example interventional radiology facilities to treat immi­
nent bleeding. Furthermore, since in the Netherlands dis­
tances between any participating hospital and the nearest 
university medical centre is always within 10-100 kilome­
tres, referral of patients is generally accepted and easy. A 
second possible disadvantage is the exclusion criteria 'pre­
vious placement of percutaneous drains'. This may apply 
to a considerable num ber of patients. The steering com­
mittee will repeatedly address this issue in meetings with 
referring physicians. Finally, in a trial with a rare disease 
such as infected necrotizing pancreatitis accrual is 
expected to be difficult. If after the first year less than 85% 
of the expected patients are recruited the study group will 
invite (inter-)national centres to join PANTER.
Conclusion
PANTER is a randomised controlled multicenter trial set 
out to reveal a reduction in major morbidity by introduc­
ing a minimally invasive 'step-up approach' instead of 
maximal necrosectomy by laparotomy in patients with 
(suspected) infected necrotizing pancreatitis. Results are 
expected by 2008.
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Buskens, MS van Leeuwen, UMC Utrecht; MA Boer- 
meester, JS Lameris, AMC Amsterdam; CHJ van Eijck, 
ErasmusMC Rotterdam; TL Bollen, B van Ramshorst, St. 
Antonius Hospital Nieuwegein; RJ Ploeg, HS Hofker, 
UMC Groningen; H van Goor, Radboud University 
Nijmegen MC; CHC Dejong, University Hospital Maas­
tricht; AFM Schaapherder, Leiden UMC.
M o n ito rin g  C om m ittee
FL Moll (Chairman), KG Moons, M Samsom, M Prokop, 
UMC Utrecht; PB Soeters, University Hospital Maastricht.
Key staff at coordinating centre
HC van Santvoort (principal investigator), MGH Bes­
selink (trial infrastructure), VJM Zeguers (trial research 
nurse), AJ Roeterdink (trial research nurse), GA Cirkel 
(investigator), J Oors (auditor), E Buskens (epidemiolo­
gist), RER Veen, JW Maaskant (internet randomisation 
and data entry), HG Gooszen (supervisor), University 
Medical Center Utrecht.
Clinical centres and investigators
The last investigator per hospital is the local principal 
investigator. All investigators are from departments of 
Surgery, unless specified (G) departments of Gastroenter­
ology or (R) departments of Radiology. University Hospi­
tal Groningen: HS Hofker, DM van Dullemen (G), EJ van 
der Jagt (R), RJ Ploeg; UMC St. Radboud Nijmegen: JBMJ 
Janssen (G), SP Strijk (R), H van Goor; University Hospi­
tal Maastricht: JW Greve, W Hameeteman (G), R Vliegen 
(R), CHC Dejong; Erasmus Medical Center Rotterdam: EJ 
Kuipers (G), JJ Hermans (R), JF Lange, CHJ van Eijck; Aca­
demic Medical Center Amsterdam: MJ Bruno (G), JS 
Lameris (R), DJ Gouma, MA Boermeester; Leiden Univer­
sity Medical Center: A Haasnoot, AFM Schaapherder; Vrije 
Universiteit Medical Center Amsterdam: CJ Mulder (G), 
MA Cuesta; Canisius Wilhelmina Hospital Nijmegen: AC 
Tan (G), PH Haarbrink (R), AHM Molenaar (R), C Ros- 
man; Medical Center Rijnmond Zuid: E van der Harst;
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Gelderse Vallei Hospital Ede: PhM Kruyt, BJM Witteman 
(G); Meander Medical Center Amerfoort: MA Brink (G), 
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Delft: LPS Stassen, CJM Bolwerk (G), TM Karsten; Medical 
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(G), AB Huisman (R), RJ de Wit; Gelre Hospitals Apel­
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Tuynman (G), BM Wiarda (R), APJ Houdijk; Medical 
Center Leeuwarden: P Spoelstra (G), JA Dol (R), JPEN 
Pierie; St. Elisabeth Hospital Tilburg: AWM van Milligen 
de Wit (G), CJHM van Laarhoven, St. Antonius Hospital 
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